

Meridian Receives Endorsement From Recognized Cardiologist for Digital Pulse Analyzer

SEOUL, South Korea, Nov. 30, 2005 (PRIMEZONE) -- *Meridian Co., Ltd. (Meridian)* (OTC BB:MRDAF.OB - News) today announced that it has received a positive endorsement of its Digital Pulse Analyzer product from Dr. Saul Isserow. The study performed by Dr. Isserow was undertaken completely independently without any input or influence by any *Meridian* associate or principal.

Dr. Isserow is a *Royal College Certified Cardiologist*, a staff cardiologist at *University of British Columbia Hospital* and *Vancouver General Hospital* and holds the positions of Director of the *Vancouver General Hospital Centre for Cardiac Rehabilitation and Risk Factor Management* and Associate Director of Cardiology at the *University of British Columbia Hospital*.

The study was conducted in conjunction with an existing program to measure the effects of training on semi-professional tri-athletes, in cooperation with the *Kinesiology Department of the University of British Columbia*. Parameters of the study included analysis prior to and following competition in a triathlon.

Conclusions of the study relating particularly to the Digital Pulse Analyzer include:

- 1) The machine is noninvasive and safe
- 2) The machine is accurate at measuring the parameters it is designed to measure
- 3) The measurement of heart rate variability, a marker for cardiovascular health, is accurate.

About Digital Pulse Analyzer (DPA)

The DPA accurately measures the elasticity of small and large arteries and provides health care practitioners with critical information regarding arterial aging. This FDA-approved device is inexpensive, non-invasive and can provide results in minutes. Accumulating evidence suggests that abnormalities in the pulsatile characteristics of arteries occur early in the disease process associated with increased cardiovascular risk, and can be favorably modified by therapeutic interventions.

Meridian feels that use of the DPA can help caregivers reduce cardiovascular disease in their patient populations through early detection and prevention and ultimately assist to decrease the associated financial costs placed on the healthcare industry. Cardiovascular disease is the number one killer in the United States with an estimated economic cost of approximately \$298 billion.

Meridian is committed to the ongoing global research and advancement of integrative medical products that contribute to the better health of humanity.